Mechanistically, cardamonin blocked NF-κB and MAPK signaling pathways, including inhibition of NF-κB p65 nuclear translocation and downstream target gene expression, demonstrating its potential as a therapeutic agent for IBD. This evidence concerns the gene NFKB1 and irritable bowel syndrome.